EMERYVILLE, CA, Feb. 21 /PRNewswire/ - NovaCal Pharmaceuticals, Inc. announced today that it has changed the Company’s name to NovaBay Pharmaceuticals, Inc.
About NovaBay Pharmaceuticals
NovaBay is a clinical stage biopharmaceutical company committed to developing its proprietary class of non-antibiotic anti-infective compounds, known as Aganocide(TM) compounds, and products based thereon. The Aganocide (TM) compounds destroy bacteria by attacking multiple sites and are also effective against bacteria that are protected by biofilm. NovaBay’s drug development programs are aimed at treating or preventing infections that have a major impact on patients including those caused by multi-drug resistant bacteria. NovaBay’s internal programs largely focus on hospital acquired infections that cause increased morbidity and mortality and that are difficult to treat with existing antibiotics. NovaBay entered into a research collaboration and license agreement with Alcon in 2006 for the development of the Aganocide(TM) compounds for use in the eye, ear and sinus, as well as in contact lens solutions. For more information on NovaBay please visit www.novabaypharma.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). NovaBay Pharmaceuticals, Inc. (the"Company”) disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing, scope or expected outcome of the Company’s or its partner’s clinical development of its drug candidates, the potential benefits of the Company’s drug candidates and the size of the potential market for the Company’s potential products. Such statements are based on management’s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the Company’s drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the Company’s drug candidates that could slow or prevent product approval or market acceptance (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), the uncertainty of patent protection for the Company’s intellectual property or trade secrets, the Company’s ability to obtain additional financing if necessary and unanticipated research and development and other costs.
NovaBay Pharmaceuticals, Inc.
CONTACT: Theresa Granados, NovaBay Pharmaceuticals, (510) 899-8870,investorrelations@novacal.com, www.novabaypharma.com; Christina Bessant,Equicom Group (416) 815-0700 x269, cbessant@equicomgroup.com
